Comparison of the efficacy of two therapeutic regimens for primary nocturnal enuresis; oxybutnin plus desmopressin versus desmopressin in pediatric patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201301117892N4

Enrollment

Registered

2013-01-28

Start date

2012-08-31

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary nocturnal enuresis. Nonorganic enuresis

Interventions

Intervention 1: In combination therapy group: Desmopressin nasal spray will be administered 1 puff/night and oxybutinin 0.5 to 1 tablet 3 times a day as needed for three months. Intervention 2: In on

Treatment - Drugs

In combination therapy group: Desmopressin nasal spray will be administered 1 puff/night and oxybutinin 0.5 to 1 tablet 3 times a day as needed for three months.

In one-drug group: Desmopressin nasal spray will be administered 1puff/night for 3 months.

Eligibility

Sex/Gender

All

Age

5 Years to 18 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: (5 to 18 year-old patients with primary nocturnal enuresis) Exclusion criteria: (to have neurogenic bladder; CNS disorders; secondary nocturnal enuresis; occurrence of drug side effects)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Frequency of nocturnal urination in a week. Timepoint: weekly for 12 weeks. Method of measurement: Using a questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAnoosh Azarfar

Tabriz University of Medical Sciences

azarfar132@yahoo.com+98 41 1658 4153

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026